0000000000630414

AUTHOR

David Zucman

showing 8 related works from this author

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study

2019

Background The association between liver stiffness measurements (LSM) and mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking sustained virological response (SVR) into account needs further study. Methods HIV/HCV participants in the French nation-wide, prospective, multicenter ANRS CO13 HEPAVIH cohort, with ≥1 LSM by FibroScan (FS) and a detectable HCV RNA when the first valid FS was performed were included. Cox proportional hazards models with delayed entry were performed to determine factors associated with all-cause mortality. LSM and SVR were considered as time dependent covariates. Results 1,062 patients were included from 2005 to 2015 …

MaleRNA virusesSustained Virologic ResponseMetabolic disordersSocial SciencesHIV InfectionsHepacivirusmedicine.disease_causeGastroenterology0302 clinical medicineImmunodeficiency VirusesRisk FactorsPsychologyAlcohol consumptionProspective Studies030212 general & internal medicineProspective cohort studyPathology and laboratory medicineMultidisciplinaryDeath ratesCoinfectionHepatitis C virusMortality rateQHazard ratioRvirus diseasesHepatitis CMiddle AgedMedical microbiologyAddicts3. Good healthLiverDrug usersVirusesCohortElasticity Imaging TechniquesMedicineFemale030211 gastroenterology & hepatologyFrancePathogensResearch ArticleCohort studyAdultmedicine.medical_specialtyScienceHepatitis C virusLiver fibrosisAddictionGastroenterology and HepatologyAntiviral AgentsMicrobiology03 medical and health sciencesPopulation MetricsInternal medicineRetrovirusesmedicineHumansMortalityLiver diseasesProportional Hazards ModelsNutritionMedicine and health sciencesBiology and life sciencesFlavivirusesPopulation Biologybusiness.industryProportional hazards modelLentivirusOrganismsViral pathogensHIVHepatitis C Chronicmedicine.diseaseHepatitis virusesMicrobial pathogensDiet[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessPLOS ONE
researchProduct

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

2022

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing como…

EğitimSocial Sciences and HumanitiesInformation Security and ReliabilitySocial Sciences (SOC)Sosyal Bilimler ve Beşeri BilimlerEpidemiologyEDUCATION & EDUCATIONAL RESEARCHTemel Bilimler (SCI)BİLGİSAYAR BİLİMİ BİLGİ SİSTEMLERİMATHEMATICSSociology[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesProspective StudiesCOMPUTER SCIENCE INFORMATION SYSTEMSSTATISTICS & PROBABILITYMatematikBilgisayar Bilimi UygulamalarıComputer SciencesBilgi Güvenliği ve GüvenilirliğiEĞİTİM VE EĞİTİM ARAŞTIRMASIBİLGİ BİLİMİ VE KÜTÜPHANE BİLİMİBilgi sistemiComputer Science ApplicationsKütüphane ve Bilgi BilimleriHospitalizationNatural Sciences (SCI)Physical SciencesEngineering and TechnologySosyal Bilimler (SOC)Bilgisayar BilimiStatistics Probability and UncertaintyInformation SystemsHumanStatistics and ProbabilityHumans; Pandemics; Prospective Studies; SARS-CoV-2; COVID-19; HospitalizationSOCIAL SCIENCES GENERALLibrary and Information SciencesEducationSDG 3 - Good Health and Well-beingLibrary SciencesINFORMATION SCIENCE & LIBRARY SCIENCEİstatistik ve OlasılıkHumansSosyal ve Beşeri BilimlerBilgisayar BilimleriSocial Sciences & HumanitiesEngineering Computing & Technology (ENG)SosyolojiPandemicsPandemicSARS-CoV-2İSTATİSTİK & OLASILIKCOVID-19Mühendislik Bilişim ve Teknoloji (ENG)İstatistik Olasılık ve BelirsizlikSosyal Bilimler GenelCOMPUTER SCIENCEProspective StudieFizik BilimleriViral infectionMühendislik ve TeknolojiKütüphanecilik
researchProduct

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a …

2022

Invasive mechanical ventilation; COVID-19; Critical care Ventilación mecánica invasiva; COVID-19; Cuidado crítico Ventilació mecànica invasiva; COVID-19; Atenció crítica Background Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods This is a multin…

:enfermedades respiratorias::trastornos respiratorios::insuficiencia respiratoria [ENFERMEDADES]COVID-19; Critical care; High flow nasal cannula; Invasive mechanical ventilationRespiració artificialCritical Care and Intensive Care Medicine[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractCOVID-19 (Malaltia) - Tractament[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCOVID-19; Critical care; High flow nasal cannula; Invasive mechanical ventilation; Humans; Prospective Studies; SARS-CoV-2; Tachypnea; COVID-19; Respiratory Insufficiency:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]HumansProspective StudiesInvasive mechanical ventilation:Otros calificadores::/terapia [Otros calificadores]TachypneaInsuficiència respiratòria - TractamentSARS-CoV-2:Therapeutics::Therapeutics::Respiratory Therapy::Respiration Artificial::Noninvasive Ventilation [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]COVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:Other subheadings::/therapy [Other subheadings]:terapéutica::terapéutica::terapia respiratoria::respiración artificial::ventilación no invasiva [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Respiratory Tract Diseases::Respiration Disorders::Respiratory Insufficiency [DISEASES]High flow nasal cannulaProspective StudieCritical careRespiratory InsufficiencyHumanCritical Care
researchProduct

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Stu…

2016

International audience;  Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of 100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.

AdultMaleHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusSerology03 medical and health sciences0302 clinical medicineImmunogenicity Vaccine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveHepatitis B virus HBVImmunology and AllergyMedicineHumansHepatitis B Vaccines030212 general & internal medicineProspective StudiesHepatitis B AntibodiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyVaccines Syntheticbiologybusiness.industryImmunogenicityvirus diseasesMiddle AgedHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyImmunologybiology.proteinHIV-1030211 gastroenterology & hepatologyFemaleAntibodybusiness
researchProduct

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort

2017

International audience; Background & aims: There is little data available on the use of new oral direct-acting antiviral (DAA) regimens to treat human immunodeficiency virus and hepatitis C virus (HIV/HCV) co-infected patients in real-life settings. Here, the efficacy and safety of all-oral DAA-based regimens in HIV/HCV-co-infected patients enrolled in the French nationwide ANRS CO13 HEPAVIH observational cohort are reported.Methods: HIV/HCV-co-infected patients enrolled in the ANRS CO13 HEPAVIH observational cohort were included if they began an all-oral DAA-based regimen before 1st May 2015 (12-week regimens) or 1st February 2015 (24-week regimens). Treatment success (SVR12) was defined b…

Malemedicine.medical_specialtyHepatitis C virus[SDV]Life Sciences [q-bio]Integrase inhibitorHIV Infectionsmedicine.disease_causeAntiviral AgentsHIV/HCV co-infectionCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineparasitic diseasesmedicineHumans030212 general & internal medicineAdverse effectHepatologyReverse-transcriptase inhibitorbusiness.industryCoinfectionRibavirinvirus diseasesHepatitis C ChronicMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthRegimenSustained virological responseLogistic ModelschemistryImmunologyCohort030211 gastroenterology & hepatologyFemaleAll-oral DAAbusinessCohort studymedicine.drug
researchProduct

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

2023

Abstract Background We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admiss…

MaleEpidemiologyMESH: HospitalizationMESH: Proportional Hazards ModelsMESH: Risk FactorsRisk FactorsMESH: Childcohort studyMESH: COVID-19HumansMESH: SARS-CoV-2ChildProportional Hazards ModelsMESH: HumansMESH: Middle AgedSARS-CoV-2COVID-19risk of deathGeneral MedicineMiddle AgedCOVID-19; SARS-CoV-2; co-morbidities; cohort study; risk of death; symptoms; treatmentsMESH: MaleHospitalizationIntensive Care Unitsco-morbiditiestreatmentssymptomsMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCOVID-19/therapy
researchProduct

Association of country income level with the characteristics and outcomes of critically ill patients hospitalized with acute kidney injury and COVID-…

2023

Introduction Acute kidney injury (AKI) has been identified as one of the most common and significant problems in hospitalized patients with COVID-19. However, studies examining the relationship between COVID-19 and AKI in low- and low-middle income countries (LLMIC) are lacking. Given that AKI is known to carry a higher mortality rate in these countries, it is important to understand differences in this population. Methods This prospective, observational study examines the AKI incidence and characteristics of 32,210 patients with COVID-19 from 49 countries across all income levels who were admitted to an intensive care unit during their hospital stay. Results Among patients with COVID-19 ad…

acute kidney injurycovid-19NephrologyKidney International Reports
researchProduct

The value of open-source clinical science in pandemic response

2021

International audience

Biomedical Research[SDV]Life Sciences [q-bio]Clinical scienceGlobal HealthCorrectionsMicrobiology1117 Public Health and Health Services1108 Medical MicrobiologyPandemicEconomicsHumansISARIC Clinical Characterisation GroupPandemicsCOVID-19/epidemiologyActuarial scienceInformation DisseminationSARS-CoV-2CommentISARICCOVID-191103 Clinical SciencesCommunicable Disease Control/methodsInfectious DiseasesOpen sourceCommunicable Disease ControlCOVID-19; Communicable Disease Control; Global Health; Humans; SARS-CoV-2; Biomedical Research; Information Dissemination; PandemicsValue (mathematics)HumanThe Lancet Infectious Diseases
researchProduct